By Jeremiah Velasquez, FNP-BC, AGACNP-BC
The EPA in your fish oil may not be doing what you think it's doing.
I don't mean EPA is useless — it isn't. But here's what the research actually shows: when scientists blocked the conversion of EPA to its downstream metabolite inside endothelial cells, EPA's ability to repair blood vessels disappeared entirely. Not diminished. Gone. The vascular benefit that's been credited to EPA for decades is, at the molecular level, a DPA story.
DPA — docosapentaenoic acid — is the third long-chain omega-3. It sits between EPA and DHA in the metabolic chain, and it's been functionally invisible in the supplement industry for one simple reason: the industrial process used to concentrate fish oil removes it. The cleaner the label, the more DPA has likely been refined away.
As a double board-certified nurse practitioner who's spent years working with patients on cardiovascular optimization protocols, I've watched fish oil recommendations stall because people are optimizing the wrong variables. Dose isn't the issue. Form isn't always the issue. What's missing from the conversation — and from most bottles — is DPA omega-3.
The EPA story has a plot hole
EPA has dominated omega-3 research for good reason. It competes with arachidonic acid for the same enzymatic binding sites, reducing the synthesis of pro-inflammatory signaling molecules. In patients I've managed with elevated inflammatory markers, therapeutic EPA doses move the needle. That part of the mechanism is real and well-established.
But vascular repair is a different biological process than inflammation suppression — and this is where EPA's story gets complicated.
What the Boyden chamber studies revealed
In studies using the modified Boyden chamber technique — a standard method for measuring cell migration — researchers compared how efficiently EPA and DPA stimulated the movement of endothelial cells. Endothelial cell migration is the first step in repairing a damaged vessel wall. When the surface of an artery is disrupted by oxidative stress, elevated glucose, or hypertension, endothelial cells need to migrate across the injury site to restore the barrier before LDL and inflammatory cells infiltrate the underlying tissue.
The results were striking. DPA achieved maximal endothelial migration at a concentration of 0.5 µM. EPA required 5.0 µM — exactly ten times higher — to produce the same effect.
That potency gap alone would be enough to make DPA worth discussing. But the more significant finding came next: when researchers inhibited the enzyme that converts EPA into DPA inside the endothelial cell, EPA's migratory benefit was abolished. Not reduced — abolished. The data indicates that EPA's vascular repair signal is mediated through its conversion to DPA, not through EPA itself.
What this means practically: if you're not getting DPA directly from your supplement, your body has to manufacture it from EPA via a metabolic conversion step that varies by individual, age, and inflammatory load. That conversion is an added variable — one that becomes less reliable exactly when vascular repair is most needed.
There's one more detail worth noting. DPA stimulates endothelial cell migration selectively. It has no stimulatory effect on smooth muscle cell migration. That distinction matters: smooth muscle proliferation into the arterial wall is a driver of plaque thickening and arterial stiffening. DPA promotes surface healing without triggering the pathological remodeling that makes vessel disease worse. That's not a coincidence of mechanism — it's a specificity that EPA, operating upstream, doesn't replicate.
What DPA omega-3 actually does inside your blood vessels
Most omega-3 conversations are built around one idea: reduce inflammation. And that framing isn't wrong — it's just incomplete. Inflammation suppression is a passive endpoint. What DPA initiates is something categorically different: an active repair program.
The distinction matters clinically. I've had patients come in with controlled inflammatory markers — CRP in range, lipid panels managed — who still showed signs of suboptimal vascular function on testing. What was missing wasn't suppression. It was resolution. The body wasn't clearing the damage efficiently, and no amount of additional EPA was going to fix that.
Why stopping inflammation isn't the same as resolving it
The body's inflammatory response runs in two phases. The first phase is initiation — immune cells flood the site, cytokines signal danger, blood flow increases. EPA's primary role is here: it competes with pro-inflammatory signaling molecules and dials the response down.
The second phase is resolution — the active clearance of cellular debris, apoptotic cells, and necrotic material from the site of injury. This phase doesn't happen automatically. It requires specific molecular signals called Specialized Pro-resolving Mediators, or SPMs. Think of them as the "stop and clean up" signal after the immune response.
DPA is a primary substrate for these resolution signals. DPA-derived resolvins and protectins act at extremely low concentrations — picogram to nanogram range — binding to specific receptors that trigger macrophage polarization. In the inflammatory state, macrophages operate in M1 mode: pro-inflammatory, cytokine-producing, driving further damage to the arterial wall. DPA-derived resolution signals push macrophages into M2 mode — the repair and clearance phenotype — with a high capacity for engulfing and removing the debris that accumulates in damaged arterial tissue.
That debris clearance is directly relevant to plaque stability. The unstable plaques most likely to rupture and cause acute cardiovascular events aren't necessarily the largest — they're the ones with a large necrotic core, the result of accumulated cellular waste the body failed to clear. DPA-driven resolution is the mechanism that prevents that core from forming.
There's also an emerging finding worth flagging as preliminary: recent research has identified a family of DPA-derived mediators called 13-series resolvins that appear to be significantly enhanced by atorvastatin. The mechanism involves statin-modified enzyme activity redirecting DPA metabolism toward pro-resolving compounds rather than inflammatory ones. This may partially explain why statins provide cardiovascular benefits beyond cholesterol reduction — but this research is early, and I'd call it mechanistically interesting rather than clinically actionable on its own.
DPA's second major mechanism operates in parallel: endothelial progenitor cell mobilization. Beyond stimulating the migration of existing endothelial cells at the injury site, DPA upregulates signaling molecules that recruit bone marrow-derived repair cells into circulation and direct them toward sites of vascular damage. It's a dual-action repair program — local migration and systemic recruitment, running simultaneously.
The mortality data that doesn't get talked about
I want to be precise about how I'm framing this section, because compliance matters here. The data I'm referencing measures circulating DPA levels in blood — not DPA supplementation. Association, not intervention. That distinction is real, and I'll hold it.
With that said: the Cardiovascular Health Study — a large prospective cohort following older adults over time — found that individuals in the highest quintile of plasma DPA levels had a 23% lower risk of total mortality compared to those in the lowest quintile. For fatal stroke specifically, higher DPA levels were associated with a 47% risk reduction — a stronger protective association than either EPA or DHA showed independently in the same dataset.
The stroke finding makes biological sense given DPA's platelet activity. DPA inhibits platelet aggregation more effectively than EPA or DHA, reducing the likelihood of obstructive clot formation in the small vessels of the brain — while simultaneously supporting the structural integrity of those vessels through the endothelial repair mechanisms described above.
What the data points toward is something I think of as the trinity effect of long-chain omega-3s:
- EPA dials down the pro-inflammatory signal — plaque stabilization, cytokine reduction
- DHA maintains membrane fluidity and structural integrity in neural and cardiac tissue
- DPA drives active repair and resolution — the mechanism that EPA and DHA don't fully cover on their own
These aren't redundant functions. They're sequential. Suppressing inflammation without resolving it is like turning off a fire alarm without addressing the smoke. The clinical picture I see in practice — patients who are "optimized on paper" but still not where they should be — often reflects that gap.
Why most fish oil doesn't contain meaningful DPA
Here's the part that doesn't get discussed in the supplement industry's marketing materials, because it implicates the refining process those brands are selling as a quality feature.
To concentrate EPA and DHA into high-potency capsules, manufacturers use a process called molecular distillation — a vacuum-based thermal process that separates fatty acids by their vapor pressure profiles. It's effective at removing environmental contaminants and elevating EPA and DHA concentrations. The problem is what happens to DPA in the process.
DPA has a different chain length and saturation profile than EPA and DHA. Its specific vapor pressure characteristics cause it to be removed during the same "stripping" phases designed to eliminate toxins and saturated fats. Compounding this, DPA is thermally sensitive — at the temperatures required for distillation (150–200°C), it's highly susceptible to oxidation. In high-purity concentrates marketed at 80%, 90%, or higher EPA content, DPA is effectively deleted.
The consumer reading "90% EPA" on a label is looking at a description of what's been removed, not just what's been concentrated.
TG vs. ethyl ester — what the absorption gap actually means
The form issue runs alongside the DPA depletion issue, and they compound each other.
In natural marine sources, omega-3s exist as triglycerides — the same molecular structure your digestive system is built to process. Industrial concentration typically converts them to ethyl esters, a synthetic form where the fatty acid is bound to an ethanol molecule rather than a glycerol backbone.
Pancreatic lipase — the enzyme responsible for fat digestion — hydrolyzes triglyceride-form omega-3s 10 to 50 times more efficiently than ethyl ester forms. The downstream absorption difference is significant: natural triglyceride forms absorb at approximately 68–70%, while ethyl ester forms can drop to around 20% when taken with a low-fat meal.
Beyond the absorption gap, ethyl ester fatty acids require additional liver processing to remove the ethanol molecule before entering circulation — introducing metabolic lag and, potentially, oxidative burden at the point of processing.
Natural triglyceride form preserves DPA. Ethyl ester form degrades it and absorbs a fraction of what's there. If your fish oil is an ethyl ester concentrate, you're dealing with both problems simultaneously.
What a complete omega-3 profile looks like
The research on DPA points toward a specific formulation principle: full-spectrum matters more than high concentration.
Based on the endothelial migration data, 50 mg of DPA provides a vascular repair signal biologically equivalent to approximately 500 mg of EPA — because DPA operates at one-tenth the concentration threshold. That isn't a dosing argument for replacing EPA. EPA's anti-inflammatory role is real and necessary. It's an argument for why DPA needs to be present in the first place, and why its absence from most concentrated fish oils represents a meaningful gap — not a rounding error.
A complete omega-3 profile, delivered in natural triglyceride form, addresses the full sequence:
- Structural foundation (DHA): Maintains the high-fluidity membranes of cardiac, neural, and ocular tissue — the substrate on which signaling runs
- Inflammatory suppression (EPA): Competitively reduces pro-inflammatory eicosanoid synthesis, stabilizing plaques and dampening the initial insult to the vessel wall
- Active repair and resolution (DPA): Orchestrates debris clearance, stimulates endothelial cell migration, mobilizes systemic repair cells — the phase that EPA and DHA don't cover
This is why I formulated CardioFuel™ Omega Complex to preserve the full DPA fraction using a gentle, full-spectrum processing method that keeps the natural triglyceride structure intact. Not because DPA is a novel marketing angle — but because leaving it out means delivering two-thirds of a mechanism and calling it complete.
Frequently asked questions
Does my current fish oil contain DPA? Probably not in meaningful amounts — especially if it's marketed as high-concentration EPA or DHA. Check the supplement facts panel for a DPA listing. Most concentrated ethyl ester products won't include it, and many don't test for it. Full-spectrum, triglyceride-form oils from minimally processed sources are most likely to retain it.
How is DPA different from DHA if they're structurally similar? They're close in chain length but distinct in function. DHA is primarily a structural molecule — it integrates into cell membranes, especially in the brain and eyes, where it supports membrane fluidity and neural signaling. DPA is primarily a signaling and repair molecule — it triggers endothelial migration, drives resolution-phase immune activity, and serves as a metabolic reservoir that can convert back to EPA under physiological stress. Similar structure, different job.
Do I need DPA if I'm already taking high-dose EPA? The research suggests that relying on EPA-to-DPA conversion as your primary DPA source introduces an unreliable variable. Conversion efficiency declines with age, chronic inflammation, and metabolic stress — exactly the conditions where vascular repair is most critical. Direct DPA intake bypasses that conversion dependency. High-dose EPA remains valuable for its anti-inflammatory role; DPA adds the repair and resolution capacity that EPA alone doesn't provide.
The reframe
The supplement industry has trained consumers to read "high purity" as a quality signal. More EPA per capsule, less everything else — that's what premium has looked like for the past two decades.
But omega-3 physiology isn't a single-molecule story. Vascular health runs in phases: suppression, resolution, repair. EPA handles the first. DPA handles the rest. A fish oil that's been refined down to one molecule — regardless of how concentrated it is — has optimized for the label, not the biology.
The most therapeutically complete omega-3 profile looks a lot like what you'd get from the ancestral marine diet humans evolved on: full-spectrum, minimally processed, with the DPA fraction intact. That's not a marketing position. It's a description of what the research actually supports.
If you're already investing in omega-3 supplementation and want to make sure your formulation covers the full mechanism, CardioFuel™ Omega Complex is built around this principle — natural triglyceride form, full-spectrum profile, DPA preserved.